Covid-19 and the renin-angiotensin system

Zang et al. Angiotensin-converting Enzyme 2 (ACE2) as a SARS-CoV-2 Receptor: Molecular Mechanisms and Potential Therapeutic Target Intensive Care Med. 2020 Apr;46(4):586-590. doi: 10.1007/s00134-020-05985-9.

Xiamoning et al. Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis Hypertension. 2020 May 27.doi: 10.1161/HYPERTENSIONAHA.120.15572

Lamas et al. Angiotensin II Suppression in SARS-CoV-2 Infection: A Therapeutic Approach Nefrologia. 2020 Apr 30;S0211-6995(20)30044-8.doi: 10.1016/j.nefro.2020.04.006

Roberto et al. Therapy With Agents Acting on the Renin-Angiotensin System and Risk of SARS-CoV-2 Infection Clin Infect Dis. 2020 May 22;ciaa634.doi: 10.1093/cid/ciaa634

Sun et al. Association of Renin-Angiotensin-Aldosterone System Inhibitors With COVID-19-related Outcomes in Korea: A Nationwide Population-Based Cohort Study Clin Infect Dis. 2020 May 22;ciaa624.doi: 10.1093/cid/ciaa624.

Sunnie et al. What Solid Organ Transplant Healthcare Providers Should Know About Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Clin Transplant. 2020 May 23;e13991.doi: 10.1111/ctr.13991.

Neda et al. Angiotensin Converting enzyme-2 as Therapeutic Target in COVID-19 Diabetes Metab Syndr. 2020 May 12;14(4):637-639.doi: 10.1016/j.dsx.2020.05.022

Gheblai et al. Angiotensin Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System. Circ Res. 2020 Apr 8. doi: 10.1161/CIRCRESAHA.120.317015.

Cure et al. Comment on “Organ-protective Effect of Angiotensin-converting Enzyme 2 and its Effect on the Prognosis of COVID-19”. J Med Virol. 2020 Apr 8. doi: 10.1002/jmv.25848.

Kreuzt el at. Hypertension, the renin-angiotensin system, and` the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovasc Res. 2020 Apr 15. pii: cvaa097. doi: 10.1093/cvr/cvaa097.

Sarzani et al. Severe acute respiratory syndrome coronavirus 2 infection, angiotensin-converting enzyme 2 and treatment with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers. Eur J Prev Cardiol. 2020 Apr 15:2047487320918421. doi: 10.1177/2047487320918421.

Battistoni et al. Might renin-angiotensin system blockers play a role in the COVID-19 pandemic? Eur Heart J Cardiovasc Pharmacother. 2020 Apr 14. pii: pvaa030. doi: 10.1093/ehjcvp/pvaa030.

Bavishi et al. Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers. JAMA Cardiol. 2020 Apr 3. doi: 10.1001/jamacardio.2020.1282.

Sommerstein et al. Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect? J Am Heart Assoc. 2020 Apr 7;9(7):e016509. doi: 10.1161/JAHA.120.016509. Epub 2020 Apr 1.

Chen et al. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020 Mar 30. pii: cvaa078. doi: 10.1093/cvr/cvaa078.

Zhang F The potential risk of kidney vulnerable to novel coronavirus 2019 infection. Am J Physiol Renal Physiol. 2020 Mar 30. doi: 10.1152/ajprenal.00085.2020.

Li et al. Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension. Hypertens Res. 2020 Mar 30. doi: 10.1038/s41440-020-0433-1.

Meng et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 2020 Dec;9(1):757-760. doi: 10.1080/22221751.2020.1746200.

Marin et al. Facts and reflections on COVID-19 and anti-hypertensives drugs. Drug Discov Ther. 2020 Mar 26. doi: 10.5582/ddt.2020.01017.

Luis Alcocer et al. COVID-19 and the Renin, Angiotensin, Aldosterone System. A Complex Relationship. Arch Cardiol Mex. 2020;90(Supl):19-25.

PMID: 32523145 DOI: 10.24875/ACM.M20000063

Meng-Yuan Liu et al. Role and Mechanism of Angiotensin-Converting Enzyme 2 in Acute Lung Injury in Coronavirus Disease 2019. Chronic Dis Transl Med. 2020 Jun;6(2):98-105.

PMID: 32550040 PMCID: PMC7236734 DOI: 10.1016/j.cdtm.2020.05.003

Jens Vikse et al. Do Sex-Specific Immunobiological Factors and Differences in Angiotensin Converting Enzyme 2 (ACE2) Expression Explain Increased Severity and Mortality of COVID-19 in Males? Diagnosis (Berl) . 2020 Jun 4;/j/dx.ahead-of-print/dx-2020-0054/dx-2020-0054.xml.

PMID: 32549125 DOI: 10.1515/dx-2020-0054

Jameel et al. Decoy ACE2-expressing Extracellular Vesicles That Competitively Bind SARS-CoV-2 as a Possible COVID-19 Therapy. Clin Sci (Lond). 2020 Jun 26;134(12):1301-1304.

PMID: 32542396 DOI: 10.1042/CS20200623

Stéphanie Pons et al. The Vascular Endothelium: The Cornerstone of Organ Dysfunction in Severe SARS-CoV-2 Infection. Crit Care. 2020 Jun 16;24(1):353.

PMID: 32546188 DOI: 10.1186/s13054-020-03062-7

Xiaoqiang Huang et al. De novo Design of Protein Peptides to Block Association of the SARS-CoV-2 Spike Protein With Human ACE2. Aging (Albany NY). 2020 Jun 16;12.

PMID: 32544884 DOI: 10.18632/aging.103416

Xiaoqiang Zhang et al. ACE2 and COVID-19 and the Resulting ARDS. Postgrad Med J. 2020 Jun 10

PMID: 32522846 DOI: 10.1136/postgradmedj-2020-137935

Tucker et al. Myocyte Specific Upregulation of ACE2 in Cardiovascular Disease: Implications for SARS-CoV-2 Mediated Myocarditis. medRxiv. 2020 Apr 14;2020.04.09.20059204.

PMID: 32511660 PMCID: PMC7277016 DOI: 10.1101/2020.04.09.20059204

Alexandre et al. Renin-angiotensin-aldosterone System and COVID-19 Infection. Ann Endocrinol (Paris). 2020 Jun;81(2-3):63-67.

PMID: 32370986 PMCID: PMC7172808 DOI: 10.1016/j.ando.2020.04.005